STXBP6 and non-small cell lung carcinoma: In conclusion, our findings demonstrated that circ_0002346 suppressed NSCLC progression partly by targeting the miR-582-3p/STXBP6 axis in vitro and in vivo, which provided novel potential targets for NSCLC treatment.